ArticleMedical physics2025
Towards an adequate description of the dose-response relationship in BNCT of glioblastoma multiforme.
Article in Medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hypo-segmentation ofEJNMMI research · 2025Article
- Article
- Towards an adequate description of the dose-response relationship in BNCT of glioblastoma multiforme.Medical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundBoron Neutron Capture Therapy (BNCT) is a binary radiotherapy based on the intravenous administration of a borated drug to the patient and the subsequent irradiation with a low-energy neutron beam. The borated formulation accumulates in the tumor cells, and when neutrons interact with boron, a nuclear capture reaction occurs, releasing high-linear energy transfer, short-range particles that cause lethal damage to the cancer cells. Due to its selectivity, BNCT has the potential to treat aggressive brain tumors such as glioblastoma multiforme (GBM), minimizing the side effects. GBM is a brain neoplasia that poses significant treatment challenges due to its invasiveness and resistance to conventional treatments. PURPOSE: This work aims to find a suitable model for calculating the photon isoeffective dose for GBM, producing ad hoc radiobiological data to feed the model.
methodsTo describe adequately the dose-effect relation of BNCT for GBM, the following strategy has been applied 1.We studied the impact of choosing two different photon radiation types (x- or gamma- rays) 2.We assumed that the correct description of the photon-equivalent dose is obtained with the photon isoeffective dose model. This model calculates the photon dose that equals the cell survival obtained with BNCT, taking into account synergism and sub-lethal damage (SLD). 3.Survival curves as a function of the dose for the human GBM U87 cell line were constructed using the clonogenic assays for irradiation with photons (reference), neutron beam, and BNCT. 4.Survival curves were fitted with the modified linear quadratic model, using SLD repair times derived for U87. The radiobiological parameters were determined for the photon isoeffective dose model. 5.The model was applied to a clinical case that received BNCT in Taiwan. Treatment planning has been simulated using an accelerator-based designed neutron beam following the real treatment process and parameters. The results were discussed and compared to the current method, which employs relative biological effectiveness (RBE) factors to obtain BNCT dosimetry in photon-equivalent units.
resultsThe dose-survival curves have been obtained with two different photon radiation sources as the reference with a thermal neutron beam and neutrons in the presence of boron. The fitted parameters have been obtained as the input for the photon isoeffective dose and the traditional RBE model. For the first time, the radiobiological parameters of a photon isoeffective dose model were produced for BNCT of GBM. Photon isoeffective dose value can differ up to 32% using gamma photons and low-energy x-rays. Photon isoeffective dose values are lower (17%) than the RBE model currently employed in clinical trials.
conclusionThe results highlight the impact of the reference radiation chosen for the isoeffective dose calculation and the importance of feeding the model with the appropriate radiobiological parameters.The dosimetry obtained with the new radiobiological data is consistent with the dose delivered in modern stereotactic radiotherapy, enabling tumor control predictions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.